Experimental drug AL101 shows promise in shrinking rare cancer before surgery
NCT ID NCT04973683
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 39 times
Summary
This early-phase trial tests the safety and potential benefits of the drug AL101 given before standard surgery in 14 people with a rare salivary gland cancer called adenoid cystic carcinoma that has a specific genetic change (NOTCH activation). The goal is to see if AL101 can help control the tumor before it is removed. Participants receive AL101 for a short time before surgery, and researchers monitor side effects and changes in the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.